Core Viewpoint - The stock of Sino Medical Science and Technology Co., Ltd. has experienced abnormal trading fluctuations, with a cumulative decline of 30% over three consecutive trading days from August 20 to August 22, 2025, prompting a regulatory announcement regarding the situation [1][6]. Group 1: Stock Trading Abnormalities - The company's stock price closed at 32.70 yuan per share as of August 22, 2025, with significant volatility exceeding that of most peers and the Shanghai Composite Index [3][10]. - The rolling price-to-earnings (P/E) ratio of the company is reported at 2318.77, significantly deviating from the industry average P/E ratio of 34.84 [3][10]. - The trading turnover rates for August 20, 21, and 22, 2025, were 16.56%, 19.01%, and 14.54%, respectively, indicating a notable increase compared to previous levels [3][10]. Group 2: Company Disclosures and Operations - The company has not identified any significant media reports or market rumors that could impact its stock price, and it confirms that there are no undisclosed major events affecting stock trading [2][8]. - The company’s subsidiary, Sino Shenchang, received FDA breakthrough device designation for its COMETIU self-expanding intracranial drug-coated stent system and COMEX balloon microcatheter, which signifies recognition of its technological innovation [4][11]. - The breakthrough designation does not guarantee FDA approval for market entry, as further compliance with regulatory requirements is necessary [4][11]. Group 3: Financial Performance - For the fiscal years 2023 and 2024, the company reported net losses of 39.63 million yuan and 1.4978 million yuan, respectively, while the net profit for the first half of 2025 was 13.84 million yuan [5][12].

证券代码：688108 证券简称：赛诺医疗 公告编号：2025-038 赛诺医疗科学技术股份有限公司 关于股票交易异常波动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 赛诺医疗科学技术股份有限公司（以下简称"赛诺医疗"或"公司"）股票交 易于 2025 年 8 月 20 日、2025 年 8 月 21 日、2025 年 8 月 22 日连续 3 个交易日内日收 盘价格跌幅偏离值累计达到 30%，根据《上海证券交易所交易规则》《上海证券交易所 科创板股票异常交易实时监控细则》的有关规定，属于股票交易异常波动情形。 经公司自查，公司于 2025 年 7 月 22 日发布了《赛诺医疗关于公司新型药物洗 脱支架系统获得美国 FDA 附条件批准的自愿性披露公告》（公告编号：2025-029），于 2025 年 8 月 7 日发布了《赛诺医疗科学技术股份有限公司关于子公司产品获得 FDA 突 破性医疗器械认证的自愿性披露公告》（公告编号：2025-031），于 2025 年 8 月 22 日 发布了《赛诺医疗 ...

Core Viewpoint - Sino Medical experienced a significant decline in stock price, dropping 4.44% on August 22, with a total trading volume of 2.01 billion yuan and a turnover rate of 14.54% [1] Financial Performance - As of June 30, 2025, Sino Medical achieved total operating revenue of 240 million yuan, representing a year-on-year growth of 12.53% [1] - The company reported a net profit attributable to shareholders of 13.84 million yuan, marking a substantial year-on-year increase of 296.54% [1] - Key financial ratios include a current ratio of 2.395, a quick ratio of 1.917, and a debt-to-asset ratio of 29.39% [1] Stock Market Activity - Over the last three trading days, the stock has cumulatively declined by 19.1% [1] - On the same day, the net outflow of main funds was 208.97 million yuan, accounting for 10.4% of the trading volume, with large orders contributing to a net outflow of 187.02 million yuan, or 9.31% of the trading volume [1] Business Focus - Sino Medical specializes in the research, development, production, and sales of high-end interventional medical devices, with a product pipeline that includes key areas such as cardiovascular, cerebrovascular, and structural heart disease interventions [1] - The company's core product is the BuMA biodegradable drug-coated coronary stent system, which is designed and developed in-house and holds international intellectual property rights [1]

New Stock Listings - New stock "能之光" (Code: 920056) listed at an issue price of 7.21 on August 22, 2025[1] - "申科股份" (Code: 002633) has a tender offer period from July 29 to August 27, 2025[1] - "抚顺特钢" (Code: 600399) has a tender offer period from August 12 to September 10, 2025[1] Abnormal Fluctuations - "赛诺医疗" (Code: 688108) reported severe abnormal fluctuations on August 19, 2025[1] - "ST苏吴" (Code: 600200) announced abnormal fluctuations on August 21, 2025[1] - "汇嘉时代" (Code: 603101) reported abnormal fluctuations on August 22, 2025[1] Other Notable Announcements - "酒鬼酒" (Code: 000799) reported an announcement on August 21, 2025[1] - "国机精工" (Code: 002046) had an announcement on August 21, 2025[1] - "全柴动力" (Code: 600218) reported an announcement on August 21, 2025[1]

Market Overview - The net inflow of main funds in the Shanghai and Shenzhen markets reached 25.419 billion yuan, with the Sci-Tech Innovation Board seeing a net inflow of 6.497 billion yuan [1] - A total of 278 stocks experienced net inflows, while 309 stocks faced net outflows [1] Sci-Tech Innovation Board Performance - On the Sci-Tech Innovation Board, 470 stocks rose, with 6 stocks hitting the daily limit, including Shengmei Shanghai and Yuntian Lefe [1] - 112 stocks declined in value [1] Key Stocks with Significant Fund Inflows - The top three stocks with the highest net inflows were: - SMIC (中芯国际) with a net inflow of 2.579 billion yuan, ranking first [2] - Haiguang Information (海光信息) with a net inflow of 1.459 billion yuan [2] - Lanke Technology (澜起科技) with a net inflow of 481.64 million yuan [2] Stocks with Continuous Fund Inflows - A total of 56 stocks have seen continuous net inflows for more than three trading days, with Huahai Qingke (华海清科) leading at 10 consecutive days [2] - The stocks with the most extended net outflows included Fudan Zhangjiang (复旦张江) with 15 consecutive days of outflows [2] Fund Inflow Rankings - The top stocks by net inflow and their respective data include: - SMIC (中芯国际): 2.579 billion yuan, 12.69% inflow rate, 14.19% increase [2] - Haiguang Information (海光信息): 1.459 billion yuan, 10.97% inflow rate, 20.00% increase [2] - Lanke Technology (澜起科技): 481.64 million yuan, 7.00% inflow rate, 8.70% increase [2] Summary of Fund Outflows - The stock with the highest net outflow was Yingshi Innovation (影石创新) with a net outflow of 332 million yuan and a decline of 4.34% [1] - Other notable outflows included Sainuo Medical (赛诺医疗) and Tiebian Heavy Industry (铁建重工) with outflows of 223 million yuan and 143 million yuan, respectively [1]

公司摊薄每股收益为0.03元，较去年同报告期摊薄每股收益增加0.02元，实现4年连续上涨，同比较去年同期上涨200.00%。 公司最新总资产周转率为0.18次，较去年同期总资产周转率增加0.01次，实现4年连续上涨，同比较去年同期上涨7.34%。最新存货周转率为0.97次，较去年 同期存货周转率增加0.24次，实现4年连续上涨，同比较去年同期上涨33.93%。 公司股东户数为1.11万户，前十大股东持股数量为1.53亿股，占总股本比例为36.89%，前十大股东持股情况如下： | 序号 | 股东名称 | 持股 | | --- | --- | --- | | 1 | 天津佳信阳光企业管理咨询有限公司 | 17.2 | | 2 | 郭彦超 | 5.47 | | 3 | 黄松浪 | 2.62 | | ব | 天津阳光广业企业管理合伙企业(有限合伙) | 2.55 | | 5 | 天津阳光德业企业管理合伙企业(有限合伙) | 1.97 | | 6 | 李广欣 | 1.89 | | 【 | 天津阳光永业企业管理合伙企业(有限合伙) | 1.61 | | 8 | 北京时代复兴投资管理有限公司-时代复兴太平1号私募证券投资基 ...

公募基金方面，本期较上一季度新披露的公募基金共计1个，即中金中证500指数增强A。本期较上一季 未再披露的公募基金共计1个，即信澳中小盘混合A。 2025年8月22日，赛诺医疗(688108.SH)发布2025年半年度报告。截至2025年8月21日，共有7个机构投资 者披露持有赛诺医疗A股股份，合计持股量达1.07亿股，占赛诺医疗总股本的25.76%。其中，机构投资 者包括天津伟信阳光企业管理咨询有限公司、天津阳光广业企业管理合伙企业(有限合伙)、天津阳光德 业企业管理合伙企业(有限合伙)、天津阳光永业企业管理合伙企业(有限合伙)、北京时代复兴投资管理 有限公司-时代复兴太平1号私募证券投资基金、北京和聚私募基金管理有限公司-和聚世然1期私募证券 投资基金、中金中证500指数增强A，机构投资者合计持股比例达25.76%。相较于上一季度，机构持股 比例合计下跌了0.32个百分点。 ...

Policy Developments - The State Council has agreed in principle to the "Biopharmaceutical Industry Chain Open Innovation Development Plan" for the China (Jiangsu) Free Trade Zone, aiming to create a globally influential biopharmaceutical industry hub and enhance international competitiveness [1] Industry Initiatives - The National Health Commission has issued guidelines to promote the application of artificial intelligence in ear and hearing health, focusing on the development and transformation of cutting-edge technologies in the field [2] Medical Pricing Guidelines - The National Medical Insurance Administration has released two project guidelines for medical service pricing, including the "Hernia and Thyroid Medical Service Pricing Project" and the "Digestive System Medical Service Pricing Project," integrating existing pricing projects into 25 and 150 items respectively [3] Medical Device Approvals - Zhonghong Medical's subsidiary, Shenzhen Maide Rui Na, has obtained a medical device registration certificate for an infusion pump, valid until August 19, 2030 [4] - Zhejiang Medicine has received approval for clinical trials of XC2309 injection, a first-class chemical drug intended for treating gastrointestinal ulcer bleeding [5] Financial Performance - Maipu Medical reported a 29.28% increase in revenue to 158 million yuan and a 46.03% rise in net profit to 47.3 million yuan for the first half of 2025 [6] - Sainuo Medical achieved a 12.53% increase in revenue to 240 million yuan and a remarkable 296.54% growth in net profit to 13.8 million yuan in the same period [8] - Baihua Medicine reported a revenue of 202 million yuan, a 2.95% increase, and a net profit of 25.5 million yuan, up 12.45% [9] Capital Market Activities - Linuo Pharmaceutical plans to acquire a 30% stake in Suzhou Chuangyang New Materials Technology Co., Ltd. for 84 million yuan [10] Industry Innovations - Researchers from Columbia University and Rockefeller University have developed a new therapy using bacteria to deliver viruses directly to tumors, enhancing cancer treatment efficacy [11] - Sanbo Brain Science has begun using surgical robots in certain neurosurgical procedures to improve service quality and surgical outcomes [12] Corporate Changes - Yiming Pharmaceutical announced a change in its actual controller to Yao Jinbo, following a share transfer from the previous controller [13] - Tiantan Biological received a commitment from its actual controller to resolve newly created competition issues due to a recent acquisition [14]

Group 1 - The article discusses the monitoring periods for various stocks, indicating specific start and end dates for monitoring activities [1] - Notable companies mentioned include *ST Suwu, Sainuo Medical, Dongxin Co., and Changcheng Military Industry, with specific dates for monitoring and abnormal activity [1] - Sainuo Medical appears multiple times with different monitoring periods, suggesting increased scrutiny or volatility [1] Group 2 - The monitoring periods for Sainuo Medical are from August 14, 2025, to August 27, 2025, with abnormal activity starting on August 7, 2025 [1] - Dongxin Co. has a monitoring period from August 18, 2025, to August 29, 2025, with abnormal activity starting on July 7, 2025 [1] - Changcheng Military Industry's monitoring period is from August 14, 2025, to August 27, 2025, with abnormal activity starting on July 31, 2025 [1]

公司代码：688108 公司简称：赛诺医疗 1.2重大风险提示 公司已在本报告中详细阐述了公司在经营过程中可能面临的各种风险及应对措施，具体内容详见本报告 第三节"管理层讨论与分析之风险因素"部分的阐述，敬请投资者注意投资风险。 1.3本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实性、准确性、完整 性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 1.4公司全体董事出席董事会会议。 1.5本半年度报告未经审计。 1.6董事会决议通过的本报告期利润分配预案或公积金转增股本预案 无 第一节 重要提示 1.1本半年度报告摘要来自半年度报告全文，为全面了解本公司的经营成果、财务状况及未来发展规 划，投资者应当到www.sse.com.cn网站仔细阅读半年度报告全文。 1.7是否存在公司治理特殊安排等重要事项 □适用 √不适用 第二节 公司基本情况 2.1公司简介 公司股票简况 ■ 公司存托凭证简况 □适用 √不适用 联系人和联系方式 ■ 2.2主要财务数据 单位：元 币种：人民币 ■ 2.6截至报告期末的优先股股东总数、前10名优先股股东情况表 ■■ 2.3前10名股东持 ...